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Abstract
Background: Blood vessels in tumors express higher level of aminopeptidase N (APN) than normal tissues. Evidence
suggests that the CNGRC motif is an APN ligand which targets tumor vasculature. Increased expression of APN in tumor
vascular endothelium, therefore, offers an opportunity for targeted delivery of NGR peptide-linked drugs to tumors.
Methods/Principal Findings: To determine whether an additional cyclic CNGRC sequence could improve endothelial cell
homing and antitumor effect, human plasminogen kringle 5 (hPK5) was modified genetically to introduce a CNGRC motif
(NGR-hPK5) and was subsequently expressed in yeast. The biological activity of NGR-hPK5 was assessed and compared with
that of wild-type hPK5, in vitro and in vivo. NGR-hPK5 showed more potent antiangiogenic activity than wild-type hPK5: the
former had a stronger inhibitory effect on proliferation, migration and cord formation of vascular endothelial cells, and
produced a stronger antiangiogenic response in the CAM assay. To evaluate the tumor-targeting ability, both wild-type hPK5
and NGR-hPK5 were
99 mTc-labeled, for tracking biodistribution in the in vivo tumor model. By planar imaging and
biodistribution analyses of major organs, NGR-hPK5 was found localized to tumor tissues at a higher level than wild-type hPK5
(approximately 3-fold). Finally, the effects of wild-type hPK5 and NGR-modified hPK5 on tumor growth were investigated in
two tumor model systems. NGR modification improved tumor localization and, as a consequence, effectively inhibited the
growth of mouse Lewis lung carcinoma (LLC) and human colorectal adenocarcinoma (Colo 205) cells in tumor-bearing mice.
Conclusions/Significance: These studies indicated that the addition of an APN targeting peptide NGR sequence could
improve the ability of hPK5 to inhibit angiogenesis and tumor growth.
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Introduction
In vivo panning of phage libraries in tumor-bearing animals has
proved useful for selecting peptides able to interact with proteins
expressed within tumor-associated vessels and to home to
neoplastic tissues [1]. Among the targeting probes identified thus
far, a peptide containing the NGR motif is an aminopeptidase N
(CD13) ligand that targets tumor vasculature [2].
Numerous studies have focused on the use of the NGR motif for
ligand-directed delivery of various drugs and particles to tumor
vessels [3], such as tumor necrosis factor a (TNF a) [4],
doxorubicin [5], proapoptotic peptides [6], liposome [7] and
tissue factor [8–10]. For example, the antitumor activity of NGR-
TNF a in animal models was 10–30 times stronger than that of
wild-type TNF a, whereas their toxicities were similar [4]. It has
also been reported that NGR modification of antiangiogenic
molecules, such as endostatin, could improve tumor localization
and, in consequence, effectively inhibited ovarian carcinoma
growth in athymic nude mice [11], indicating that addition of a
vascular targeting sequence NGR could enhance the biological
activity of an antitumor or antiangiogenic molecule.
Antiangiogenic therapy for solid tumors clearly destroys tumor
vasculature and reduces tumor growth [12]. Extensive research
has led to the identification and isolation of several regulators of
angiogenesis, some of which represent therapeutic targets [12,13].
Human plasminogen kringle 5 (hPK5), a proteolytic fragment of
plasminogen, is an endogenous angiogenic inhibitor [12–14].
Recombinant hPK5 displays the most potent inhibitory activity to
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naturally occurring angiogenesis inhibitors. A recombinant
hPK5 has also been shown to induce apoptosis in proliferating
endothelial cells and tumor cells [17,18]. Because of its high
efficacy, cell type selectivity, and small molecular weight, hPK5
has considerable potential in the treatment of neovascular diseases
involving solid tumors [12,13,19]. A number of earlier studies have
suggested that tumor suppression by hPK5 depends on its
antiangiogenic activity and hPK5 could have therapeutic potential
in hepatocellular carcinoma [20–22], lung cancer [23,24],
glioblastoma [25,26] and ovarian cancer [27]. Moreover, several
reports including our previous investigation have also indicated
that combination of hPK5 with other therapeutic agents, such as
ionizing radiation [26,28] and matrix metalloproteinase [29] could
remarkably enhance the antiangiogenic effect during tumor
formation. These findings prompted us to deliver hPK5 to the
tumor by a vascular-targeting approach.
To determine whether an additional NGR sequence could
improve endothelial cell homing and biological activity, hPK5 was
modified genetically to introduce an NGR motif and was
expressed in the yeast host strain GS115. Our studies showed
that NGR-hPK5 was localized to tumor tissues at a higher level
than wild-type hPK5 (approximately 3-fold). Increased accumu-
lation of NGR-hPK5 was correlated with stronger antiangiogenic
effects in vivo, and only one-fifth the dose of NGR-hPK5 was
needed for a similar antitumor effect produced by wild-type hPK5.
These studies suggested that the antiangiogenic activity of hPK5
could be further improved by addition of an NGR motif.
Materials and Methods
Cell Culture
Mouse Lewis lung carcinoma (LLC) cells, human colorectal
adenocarcinoma (Colo 205) cells and human umbilical vein
endothelial cells (HUVECs) were purchased from the American
Type Culture Collection (ATCC, Philadelphia, PA, USA). LLC
and Colo 205 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (HyClone, Logan, UT, USA) supplemented
with 10% (v/v) fetal bovine serum (HyClone, Logan, UT, USA)
and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA).
HUVECs were grown in Medium 200 (Cascade Biologics,
Portland, OR, USA) supplemented with Low Serum Growth
Supplement (LSGS). All cells were cultured in a humidified CO2
incubator at 37uC.
Cloning of NGR-hPK5 Yeast Expression Plasmid
The plasmid pPIC9K-hPK5 for the expression of human
plaminogen kringle 5 was constructed previously in our laboratory
[28]. The Pichia pastoris yeast expression system was purchased
from Invitrogen (Carlsbad, CA, USA). Restriction enzymes and
Taq DNA polymerase were purchased from TaKaRa (Dalian,
China). This clone was further modified to incorporate the
CNGRC sequence at the amino terminus. The following sets of
primers were used to modify hPK5 by PCR. NGR-hPK5 upper
primer: 59 CG CTCGAG AAA AGA TGC AAT GGT CGT
TGC GGT GGT GGT GGT GTC CTG CTT CCA GAT GTA
G3 9; lower primer: 59 GC GAATTC TAG GCC GCA CAC
TGA GGG AC 39. Amplified fragments were purified by a DNA
extraction kit, digested with Xho I and EcoR I, and then cloned
into pPIC9K vector. Plasmid DNA was linearized at the Sac I site
and used for homologous recombination into the yeast host strain
GS115 (Invitrogen, Carlsbad, CA, USA) by electroporation.
Expression and Purification of Recombinant NGR-hPK5 in
Pichia Pastoris
Pichia clones were cultured in baffled shaker flasks and induced
by methanol as described previously [28]. Methanol was
supplemented daily to a final concentration of 0.5% during the
post-culture period and cultured at 30uC for another 2 days with
vigorous shaking. The clarified supernatant was collected and
concentrated using ammonium sulfate precipitation (70% satura-
tion), then dissolved in buffer A (20 mM Tris-HCl, 1 mM EDTA,
0.5 mM PMSF, pH 8.0), and finally dialyzed against the same
buffer at 4uC. Proteins were purified by DEAE-Sepharose Fast
Flow column (Pharmacia, Piscataway NJ, USA). After loading the
sample, the column was washed with buffer B (20 mM Tris-HCl,
1 mM EDTA, pH 8.0) and eluted stepwisely with 0.1 M NaCl,
0.5 M NaCl in buffer B. The eluted protein fraction was analyzed
by Tricine-SDS-PAGE (5% stacking gel and 16.5% separating
gel). Protein concentration was determined by the Bradford assay
(BioRad, Hercules, CA, USA).
Cell Proliferation Assay
The effects of hPK5 and NGR-hPK5 on endothelial cell
proliferation were assessed by the MTT assay. HUVECs in the
exponential growth phase were seeded into a 96-well plate at a
density of 5000 cells per well. After 24 h, hPK5 or NGR–hPK5
was added to a final concentration of 1, 5, 10 or 25 mg/ml
respectively. The cells were incubated at 37uC for 48 h, then the
cell viability was determined by the colorimetric MTT [3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide] as-
say at wavelength 570 nm by TECAN Safire Fluorescence
Absorbance and Luminescence Reader (Vienna, VA, USA). The
cell viability was calculated according to the formula: Cell viability
(%)=average A570 nm of treated group/average A570 nm of control
group6100%.
Cell Migration Assay
The effects of hPK5 and NGR-hPK5 on endothelial cell
migration were assessed by the transwell assay and the wound
healing assay. The cell migration assay was performed using
transwell inserts (8.0 mm pore size, Millipore, Billerica, MA, USA)
as described previously [30]. Before the experiment, HUVECs
had been cultured in serum-free medium with hPK5 or NGR-
hPK5 (PBS used as buffer control) at a concentration of 5 mg/ml
for 16 h. Then the cells were harvested and re-suspended in the
same medium. 1610
5 cells in a volume of 0.1 ml were added to
the upper chamber, and the lower chamber was filled with 0.6 ml
of 20% FBS supplemented medium. After incubation at 37uC for
9 h, cells on the upper surface of the membrane were removed.
The migrant cells attached to the lower surface were fixed in 10%
formalin at room temperature for 30 min, and stained for 20 min
with a solution containing 1% crystal violet and 2% ethanol in
100 mM borate buffer (pH 9.0). The number of cells migrating to
the lower surface of the membrane was counted in five fields under
a microscope with a magnification of 6100. The wound healing
assay was also performed as described previously [30]. Briefly,
HUVECs plated onto fibronectin-coated (10 mg/ml) 24-well
plates were serum-starved overnight, then wounded with a
200 ml pipette tip, washed with PBS, and incubated in the
medium containing 10% FBS with hPK5 or NGR-hPK5 (PBS
used as buffer control) at a concentration of 5 mg/ml for 20 h. The
migration of the wounded cells was visualized and quantified
under a microscope with a magnification of 6100. All groups of
experiments were conducted in triplicate, and the cell number was
counted by Image-Pro Plus 6.0 software.
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Matrigel (BD Biosciences, Bedford, MA, USA) was thawed at
4uC overnight and placed in a 96-well culture plate at 37uC for 1 h
to allow gel formation. Before the experiment, HUVECs had been
cultured in the medium with hPK5 or NGR-hPK5 (PBS used as
buffer control) at a concentration of 10 mg/ml for 16 h. Then the
cells were harvested, re-suspended in the same medium and
seeded (45000 cells/cm
2) on top of the solidified Matrigel. After
incubation for 8 h at 37uC, the networks of cords were
photographed in five fields under a microscope with a magnifi-
cation of 6100. The total length of the cord structures in each
photograph was measured by AxioVision 3.1 software (Carl Zeiss,
Oberkochen, Germany). All groups of experiments were conduct-
ed in triplicate.
Chick Embryo Chorioallantoic Membrane (CAM) Assay
The CAM assay was performed as described with slight
modifications [31,32]. Fertilized White Leghorn chicken eggs
were placed in an incubator as soon as embryogenesis started and
were kept under constant humidity at 37uC. Briefly, on day 8 the
eggs were candled using a hand-held egg candler at the blunt end
of the egg to identify the air sac and prominent blood vessels.
Using a Dremel model drill (Dremel Racine, WI, USA), the CAM
was separated from the shell by making a shallow burr hole at the
blunt end of the egg. A solution of cortisone acetate (100 mg/disk,
Sigma-Aldrich, St. Louis, MO, USA) was added to all disks in
order to prevent an inflammatory response. Next, different
concentrations of hPK5, NGR-hPK5 or buffer control were
pipetted onto filter disks respectively, and the disk was then placed
on the CAM in an avascular area. The window was sealed with
sterile Scotch tape and the egg was returned to the incubator.
After additional 2-day incubation, the possible antiangiogenic
response was evaluated. CAM tissue directly below the filter disk
was fixed with the mixture of methanol and acetone (1:1) for
15 min. Tissues were washed 3 times with PBS and images were
acquired using a stereomicroscope with photo-digital attachment.
The response was scored as positive when CAM treated with the
sample showed an avascular zone ($5 mm in diameter) with very
few vessels compared with the control group, and was calculated as
the percentage of positive eggs relative to the total number of the
eggs tested. Ten eggs were used for each group, and the data was
reported as Mean 6 SD based on results from three independent
experiments.
Ethics Statements
Six-week-old female C57BL/6J and athymic nude mice, which
were purchased from the Vitalriver Animal Center (Vitalriver,
Beijing, China), were housed in environmentally controlled
conditions (22uC, a 12-h light/dark cycle with the light cycle
from 6:00 to 18:00 and the dark cycle from 18:00 to 6:00) and
maintained on standard laboratory chow. Animal welfare and
treatment were carried out in strict accordance with the Guide for
the Care and Use of Laboratory Animals (The Ministry of Science
and Technology of China, 2006) and all experimental protocols
were approved under animal protocol number SYXK(Su)2009-
0017 by the Animal Care and Use Committee of College of Life
Sciences, Nanjing University.
In Vivo Animal Tumor Model Experiment
Female C57BL/6J and athymic nude mice (age 6 weeks) were
obtained from the Vitalriver Animal Center and were acclimatized
to local conditions for 1 week. Logarithmically growing mouse
LLC and human Colo 205 cells were harvested by trypsinization
and suspended in PBS at a density of 1610
7 cells/ml. Then,
100 ml of the single-cell suspension were injected subcutaneously
into the right dorsum of C57BL/6J and nude mice. All tumor-
bearing mice were divided randomly into groups of 8–10, and
treatment was initiated on day 10 when the volume of tumor
reached about 40–50 mm
3. The mice were injected intraperito-
neally (i.p.) with hPK5 or NGR-hPK5 daily. Tumor measure-
ments were converted to tumor volume (V) as follows:
L6W
260.52, where L and W are the length and width,
respectively. Measurements were taken by the Vernier caliper.
All procedures followed approval of the Institutional Animal Care
Committee. In a separate experiment cisplatin treatment was
carried out in a regimen as described in results. Tumor sizes were
shown as Mean 6 SE and compared among groups using one-way
analysis of variance (ANOVA). To determine whether hPK5/
NGR-hPK5 in combination with cisplatin worked synergistically,
the combination index (CI) was calculated as follows: CI=AB/
(A6B). According to the tumor volume of each group, AB is the
ratio of the combination group to the control group; A or B is the
ratio of the single agent group to the control group. Thus a CI
value less than, equal to or greater than 1 indicates that the drugs
are synergistic, additive or antagonistic, respectively. A CI less
than 0.7 indicates that the drugs are significantly synergistic.
Tumor Localization
The uptakes in tumor of hPK5 and NGR-hPK5 were detected
and compared by planar imaging and biodistribution studies.
1610
6 LLC cells were injected subcutaneously in the right front
flank of female C57BL/6J mice (age 7 weeks). The mice were
subjected to planar imaging and biodistribution studies when the
tumor volume had reached 300–400 mm
3 (2–3 weeks after
inoculation).
Technetium-99 m labeling. Na
99 mTcO4 solution (2.0 ml,
.10 mCi/ml) was added to a lyophilized vial containing
0.455924 mg of NaH2PO4, 2.299752 mg of Na2HPO4,4 0mgo f
SnCl2,1 0ml of vitamin C, and 10 mg of hPK5 (or NGR-hPK5).
The vial was placed into the lead pig and was allowed to stand at
room temperature for 30 min. A sample of the resulting solution
was analyzed by radio-HPLC. The radiochemical purity (RCP)
was .95% for both
99 mTc-hPK5 and
99 mTc-NGR-hPK5 with a
very small amount (,0.5%) of [
99 mTc] colloid.
Planar imaging. Ten tumor-bearing mice were randomly
divided into two groups. Each mouse was administered with
500 mCi of
99 mTc-hPK5 or
99 mTc-NGR-hPK5 in 0.1 ml saline
via tail vein and then anesthetized with isoflurane. The mice were
placed prone on the pinhole collimator gamma camera (SIE-
MENS, symbia T6, Germany). Static images were acquired at 0.5,
1, 2, 3, 4 and 6 hours post-injection. The data were stored digitally
in a 2566256 matrix, and the acquisition count limits were set at
300 sec. For data analysis, ROIs (regions of interest) were drawn
over the tumor and the contralateral normal tissue. The SUVs
(standardized uptake value) were acquired automatically by
measuring the radioactivity in the region of interest and corrected
for body weight and injected dose. The tumor-to-contralateral
normal tissue (T/NT) ratios were calculated from the ROI
analysis as Mean 6 SD based on results from five tumor-bearing
mice for each group.
Biodistribution studies. Thirty-six tumor-bearing mice
were randomly divided into two groups. Each mouse was
administered with 500 mCi of
99 mTc-hPK5 or
99 mTc-NGR-
hPK5 in 0.1 ml saline via tail vein. Three mice of each group were
sacrificed per time point at 0.5, 1, 2, 3, 4 and 6 hours post-
injection, respectively. Blood samples were withdrawn with a
syringe from the heart. The tumor and normal organs (heart, liver,
NGR Modification of hPK5
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muscle) were excised, washed with saline and weighed. The
radioactivity was measured on a 1480 Wizard gamma counter
(Perkin-Elmer). The organ uptake was calculated as the percentage
of injected dose per gram of organ tissue (%ID/g). All radioactivity
measurements were corrected for decay. The biodistribution data
and T/NT (tumor-to-normal tissue) ratios were reported as Mean
6 SD based on results from three tumor-bearing mice at each
time point.
Determination of Vessel Density
To determine the effect of the treatments on vessel density,
immunofluorescence analysis was performed to visualize CD31-
positive endothelial cells. LLC tumors for light microscopy were
surgically resected and snap frozen. Frozen tumor sections (5 mm
in thickness) were prepared according to standard protocols.
Tumor sections (3 sections per mouse, totally 3 mice per group)
were fixed in cold acetone (4uC) for 20 min, air dried, and blocked
with 10% goat serum containing 1% BSA in PBS at room
temperature for 30 min. Then the rat anti-mouse CD31
monoclonal antibody (BD Pharmingen, Franklin Lakes, NJ,
USA) with a 1:100 dilution was applied and incubated at 4uC
overnight. Sections were rinsed in PBS 3 times for 5 min each.
DyLight 594 goat anti-rat IgG (Jackson ImmunoResearch, West
Grove, PA) secondary antibody with a 1:500 dilution was applied
at 37uC for 45 min in the dark. 49, 6-Diamidino-2-phenylindole
(DAPI, Santa Cruz Biotechnology, USA) counterstain was used to
visualize nuclear detail. Images were acquired and processed by
AxioVision 3.1 software on Carl Zeiss Axioplan 2. The number of
microvessels in the field with the highest vessel density (‘hot spots’)
was quantified according to the method as previously described
[33]. Three fields with the highest vessel density per section were
counted (with a magnification of 6200). Microvessel density was
determined by averaging the number of microvessels in the
counted fields.
Data Analysis and Statistics
Values were presented as Mean 6 SD or 6 SE. For paired
data, statistical analyses were performed using two-tailed Student’s
t-tests. For multiple comparisons, statistical analyses were per-
formed using one-way analysis of variance (ANOVA) with a
Tukey post-test. For all analyses, p,0.05 was considered
statistically significant.
Results
Expression and Purification of NGR-hPK5
The expression plasmid pPIC9K-NGR-hPK5, containing the
cDNA encoding NGR-hPK5, was transfected into Pichia pastoris
yeast strain GS115. The protein was purified by DEAE-Sepharose
Fast Flow column. Purified protein was then analyzed by Tricine-
SDS-PAGE and stained with Coomassie Blue (Fig. 1 A). The
elution fraction was further examined by western blot using anti-
human plasminogen antibody. As shown in Fig. 1 B, NGR-hPK5
migrated at 15 kDa as expected and no degradation was observed.
Characterization of the Biological Activity of NGR-hPK5
In order to assess the effect of NGR-hPK5 on angiogenesis in
vitro, endothelial cell proliferation, migration and cord morpho-
genesis assays were performed. As shown in the MTT assay (Fig. 2
A), both hPK5 and NGR-hPK5 displayed a dose-dependent
inhibitory effect on HUVEC proliferation, and NGR-hPK5
showed a more potent inhibitory effect than hPK5 (p,0.05).
The concentration of hPK5 was about 25 mg/ml when inhibiting
50% HUVEC proliferation, while for NGR-hPK5 the ED50 was
approximately 10 mg/ml. In addition to the anti-proliferation
effect, NGR-hPK5 also showed more inhibitory effect on
endothelial cell migration. Serum stimulated haptotaxis motility,
measured by the transwell motility chamber assay, was used to
examine the effect of NGR-hPK5 on HUVEC migration. The
cells migrating to the lower membrane were stained and quantified
as shown in Fig. 2 B&C. At the same dose, NGR-hPK5 showed
more significant inhibition of cell migration than wild-type hPK5
(p,0.05, 5 mg/ml dose), which reduced the migration of HUVECs
by 71.75% and 48.68% compared with control PBS group and
hPK5 group, respectively. Meanwhile, the wound-healing scratch
motility assay (Fig. 2 D&E) also revealed that, after 20 h healing
period, NGR-hPK5 greatly reduced the migration of HUVECs as
compared with hPK5 treated group or control PBS group at the
same dose (5 mg/ml). The cells migrating into the wound area
were counted. NGR-hPK5 treated group decreased the migrating
cells by 59.34% compared with the control group, and 40.32%
compared with hPK5 (p,0.05). Next, the effect of NGR-hPK5 on
cord formation of endothelial cell was examined. HUVECs
incubated on Matrigel for 8 h formed an extensive and enclosed
capillarylike structure. hPK5 and NGR-hPK5 (both at 10 mg/ml
dose) impaired the ability of HUVECs to form this structure,
resulting in an incomplete and sparse cord network (Fig. 2 F&G).
NGR-hPK5 treated group showed more significant inhibition than
hPK5 group, the cord formation in NGR-hPK5 group was
decreased by 73.88% compared with control PBS group, and
47.25% compared with hPK5 group (p,0.05). Subsequently,
chick embryo CAM model was used to evaluate the antiangiogenic
activity of NGR-hPK5 in vivo. Dried filter disks, adsorbed with
hPK5 or NGR-hPK5 at 0.8, 1.6 and 3.2 mg/embryo doses, were
implanted on the top of growing CAMs. Two days later, hPK5
and NGR-hPK5 induced a strong antiangiogenic response in the
CAM tissues in a dose dependent manner (Fig. 2 H&I), as shown
by the decreased number of branching vessels in the center of the
filter disk. At the same dose, NGR-hPK5 showed increased
antiangiogenic activity compared with the wild-type hPK5
(p,0.05). In sum, these data suggested that an additional NGR
modification to hPK5 could improve its biological activity of
antiangiogenesis in vitro and in vivo.
Figure 1. Recombinant NGR-hPK5 protein purification and
identification. A, Expressed and purified NGR-hPK5 samples were
separated by Tricine-SDS-PAGE, M: molecular weight markers. The
culture supernatant was collected and concentrated using ammonium
sulfate precipitation (70%), dissolved in buffer A (lane 1). After the ion
exchange purification by DEAE-Sepharose Fast Flow column, NGR-hPK5
was eluted with 0.1 M NaCl in buffer B (lane 2), whereas the bulk
impurities were eluted with 0.5 M NaCl in buffer B (lane 3). B, Western
blot analysis of hPK5 (lane 1) and NGR-hPK5 (lane 2) proteins using anti-
human plasminogen antibody.
doi:10.1371/journal.pone.0037132.g001
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To determine whether NGR-hPK5 could improve the antitu-
mor activity of hPK5, we used two tumor model systems. The first
model system used the mouse Lewis lung carcinoma (LLC) cell line
(Fig. 3 A). From day 0 on, the mice were injected i.p. daily for 5
days with NGR-hPK5 at 0.25, 1.25 and 2.5 mg/kg/day dose, or
with hPK5 at 1.25 mg/kg/day dose. Both hPK5 and NGR-hPK5
significantly inhibited the growth of LLC solid tumors (on day 3–
12, p,0.05, compared with control). On day 12, the mean volume
of tumor was 336.17669.15 mm
3, with 35.52% inhibition when
using hPK5 at 1.25 mg/kg/day dose. Treatment with NGR-
hPK5 resulted in dose-dependent inhibition of tumor growth, with
30.30%, 55.68% and 68.10% inhibition observed at 0.25, 1.25
and 2.5 mg/kg/day dose respectively. At the same dose NGR-
hPK5 resulted in more significant inhibition of tumor growth than
wild-type hPK5 (p,0.05, compared with wild-type hPK5 at
1.25 mg/kg/day dose), while the antitumor activity of NGR-
hPK5 at 0.25 mg/kg/day dose was similar to that of hPK5 at 5-
fold excess, i.e., hPK5-treated group at 1.25 mg/kg/day dose. The
second model used the human colorectal adenocarcinoma cell
line, Colo 205, in athymic nude mice (Fig. 3 B). NGR-hPK5 and
hPK5 were administered i.p. daily for 5 days at 2.5 mg/kg/day
dose. In this model system, i.p. injection of wild-type hPK5
inhibited tumor growth by 33.75% on day 12
(595.766119.10 mm
3). Under similar conditions, NGR-hPK5
treatment showed 54.76% inhibition (on day 9 and 12, p,0.05,
compared with wild-type hPK5).
Increased Tumor Localization of NGR-hPK5
To assess whether the improved endothelial cell binding in vitro
could translate into enhanced tumor homing in vivo, tumor
localization studies were performed.
99 mTc-labeled hPK5 or
NGR-hPK5 was injected i.v. into LLC grafting C57BL/6J mice.
Planar images were acquired at 0.5, 1, 2, 3, 4 and 6 hours post-
injection. As shown in Fig. 4 A, NGR-hPK5 exhibited an
obviously higher accumulation in tumors than hPK5 did at each
time point. The uptake in the tumor and its contralateral normal
tissue was measured from the ROI analysis and shown in Fig. 4 B,
the tumor-to-normal tissue (T/NT) ratios of NGR-hPK5 was 3.0–
4.0, while the ratios of hPK5 was 1.3–1.7. Subsequently, the
biodistribution studies of
99 mTc- NGR-hPK5 and
99 mTc-hPK5
were performed. Tumor, blood and major organs were collected,
weighed and counted on a gamma counter at the same time
schedule as described in planar imaging. The data was presented
as the percentage injected dose per gram of tissue (%ID/g) in
Fig. 5A, the tumor uptake of NGR-hPK5 was from
5.1160.46%ID/g to 3.5860.31%ID/g during 0.5 h to 6 h post-
injection, while the tumor uptake of hPK5 was from
1.7760.28%ID/g to 1.1560.06%ID/g. Consistent with the
results of planar imaging, the in vivo NGR-hPK5 tumor uptake
was significantly higher than that of hPK5 (approximately 3-fold).
Both of the proteins were excreted mainly through the kidneys, the
levels of NGR-hPK5 and hPK5 in kidneys were similar from 0.5 h
to 4 h post-injection, but the level of NGR-hPK5
(10.0662.98%ID/g) was lower than that of hPK5
(15.6562.13%ID/g) by the end of 6 h. No statistically significant
difference has been found for their respective distribution in blood,
lung, heart, liver, spleen, stomach, intestine, pancreas, brain, bone
or muscle. The tumor-to-normal tissue ratios of NGR-hPK5 and
hPK5 from the data of biodistribution studies were calculated and
compared in Fig. 5 B. The tumor/blood, tumor/lung, tumor/
heart, tumor/liver, tumor/spleen, tumor/kidney, tumor/stomach,
tumor/intestine, tumor/pancreas, tumor/brain, tumor/bone and
tumor/muscle ratios of NGR-hPK5 were all significantly higher
(p,0.05) than those of hPK5 at 1 h and 6 h. Taken together,
NGR-hPK5 showed selective targeting in the LLC tumor and did
not lead to nonspecific accumulation in other tissues.
Suppression of Tumor Neovascularization
To determine the effects of treatment on early tumor
neovascularization, we examined blood vessel density in tissue
sections from LLC tumor using anti-mouse CD31 antibody and
standard immunofluorescence techniques. LLC tumor-bearing
C57BL6/J mice were systemically treated with control saline or
with 2.5 mg/kg/day of hPK5 or NGR-hPK5 daily for 5 days, and
primary tumors were resected on day 1 after post-treatment. The
microvessel density (MVD) was estimated by the mean of CD31-
positive endothelial cells from three most vascular areas (‘hot
spots’) within the tumor section. Fig. 6 showed that wild-type and
NGR modified hPK5 treatment resulted in reduced microvessel
density by 26.34% and 51.85% compared with control respec-
tively (p,0.05). The NGR motif enhanced the antiangiogenic
effect of hPK5 on the density of blood vessels significantly, which
reduced microvessel density by 34.62% in comparison with wild-
type hPK5 (p,0.05).
Combination of Cisplatin and hPK5/NGR-hPK5 Inhibits
Tumor Growth Synergistically
To determine whether hPK5/NGR-hPK5 could improve the
antitumor activity of cisplatin chemotherapy, we used the LLC
tumor model system. From day 0 on, the mice were injected i.p.
every two days with hPK5 or NGR-hPK5 at 1.25 mg/kg/day
dose (on days 0, 2, 4, 6, 8 and 10). On the following day after each
injection with the proteins, different doses of cisplatin were
administered i.p. to the mice (on days 1, 3, 5, 7, 9 and 11). On day
18, a significant antitumor response was observed with 66.00%
inhibition when mice received cisplatin alone at a high dose
(2 mg/kg/day) (p,0.05, compared with control), while the effect
of hPK5 plus cisplatin (Fig. 7 A) resulted in 67.83% inhibition of
tumor growth compared with control, which had no statistically
significant difference from that of cisplatin alone (p.0.05).
However, as shown in Fig. 7 B, NGR-hPK5 could enhance the
Figure 2. Antiangiogenic activity assessment of NGR-hPK5. A, MTT assay. HUVECs were treated with different concentrations of hPK5 or NGR-
hPK5 (1, 5, 10 or 25 mg/ml) for 48 h. Cell viability (%)=average A570 nm of treated group/average A570 nm of control group6100%. N=4. B & C,
Transwell assay. HUVECs were treated with 5 mg/ml of hPK5 or NGR-hPK5. After 16 h pretreatment and 9 h incubation in the upper chamber, the cells
migrating to the lower membrane were stained and counted in five fields with a magnification of 6100. N=3, bar=50 mm. D & E, Wound healing
assay. HUVECs were treated with 5 mg/ml of hPK5 or NGR-hPK5. After 20 h healing period, the cells migrating into the wound area were visualized
and quantified with a magnification of6100. N=3, bar=100 mm. F & G, Cord morphogenesis assay. HUVECs were treated with 10 mg/ml of hPK5 or
NGR-hPK5. After 16 h pretreatment and 8 h incubation on Matrigel, the networks of cords were photographed and the total length of the cord was
measured in five fields under a microscope with a magnification of6100. N=3, bar=100 mm. H & I, Chick CAM assay of angiogenesis. Representative
CAMs from 8-day-old chick embryos, which were treated with different doses of hPK5 or NGR-hPK5 (0.8, 1.6 or 3.2 mg/egg) for 48 h. The data was
calculated as the percentage of the positive eggs (formation of avascular zones $5 mm in diameter) relative to the total eggs tested. N=10,
bar=600 mm. PBS was used as buffer control. All experiments were conducted in triplicate. * p,0.05 compared with hPK5, ‘ p,0.05 compared with
control.
doi:10.1371/journal.pone.0037132.g002
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mean tumor size in combination therapy group was significantly
reduced to 11.34% of the control group and 33.45% of the
cisplatin-treated group (p,0.05, compared with cisplatin). The
combination index (CI) was 0.636, which indicated that the drugs
were significantly synergistic. Cisplatin using at a low dose
(0.5 mg/kg/day) induced border or marginal effect, but the
antitumor effect of recombinant protein plus cisplatin was stronger
than that of protein alone or cisplatin alone. As shown in Fig. 7 C,
on day 21, cisplatin or hPK5 alone therapy group resulted in
20.04% and 31.89% inhibition of tumor growth compared with
the control group, while combination therapy of hPK5 and
cisplatin resulted in 55.46% and 59.92% inhibition of tumor
growth compared with the control group and cisplatin-treated
group (p,0.05). NGR-hPK5 therapy alone showed 44.65%
inhibition of tumor growth compared with control on day 21
Figure 3. Improved inhibition of LLC and Colo 205 Tumors by NGR sequence modified hPK5 (NGR-hPK5). To determine whether NGR-
hPK5 could improve the antitumor activity of hPK5, two tumor model systems were employed. A, The first tumor model system used syngeneic
C57BL/6J mice bearing LLC tumors. From day 0 on, the mice were injected i.p. daily for 5 days with NGR-hPK5 at 0.25, 1.25 and 2.5 mg/kg/day dose,
or with hPK5 at 1.25 mg/kg/day dose. Both hPK5 and NGR-hPK5 significantly inhibited the growth of LLC solid tumors. At the same dose of 1.25 mg/
kg/day, NGR-hPK5 resulted in more significant inhibition of tumor growth than wild-type hPK5. B, The second tumor model system used athymic
nude mice bearing Colo 205 xenografts. Administered i.p. daily for 5 days at 2.5 mg/kg/day dose, the in vivo antitumor activity of NGR-hPK5 was
higher than that of hPK5 on day 12. Tumor volume was calculated by the formula (L6W
260.52). Eight mice were used in each sample unit, and the
data shown were the mean volume 6 SE. * p,0.05.
doi:10.1371/journal.pone.0037132.g003
Figure 4. Detection of hPK5 and NGR-hPK5 in tumor localization by planar imaging analysis. When the LLC tumor volume reached about
300–400 mm
3,
99 mTc-labeled hPK5 or NGR-hPK5 (500 mCi) were injected i.v. into LLC grafting C57BL/6J mice. Planar images were acquired in the
prone position at 0.5, 1, 2, 3, 4 and 6 hours post-injection. A, Representative images from the planar imaging of
99 mTc-NGR-hPK5 and
99 mTc-hPK5 at
1, 3 and 6 hours post-injection. (arrows LLC tumors) B, The tumor-to-contralateral normal tissue (T/NT) ratios were calculated from the ROI analysis.
N=5. * p,0.05 compared with hPK5.
doi:10.1371/journal.pone.0037132.g004
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37132Figure 5. Biodistribution analysis of hPK5 and NGR-hPK5 in tumor-bearing mice. When the LLC tumor volume reached about 300–
400 mm
3,
99 mTc-labeled hPK5 or NGR-hPK5 (500 mCi) were injected i.v. into LLC grafting C57BL/6J mice. Tumor, blood and major organs were
collected, weighed and counted on a gamma counter at 0.5, 1, 2, 3, 4 and 6 hours post-injection. A, The biodistribution of
99 mTc-labeld NGR-hPK5
and hPK5 in tumor, blood and normal organ (lung, heart, liver, spleen, kidney, stomach, intestine, pancreas, brain, bone and muscle) at 0.5, 1, 2, 3, 4
and 6 hours post-injection. The organ uptake was calculated as the percentage of injected dose per gram of organ tissue (%ID/g). The tumor uptake
of NGR-hPK5 was significantly higher (p,0.05) than that of hPK5. No statistically significant difference has been found in their respective distribution
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strong antitumor response with 64.52% and 68.94% inhibition
compared with the control group and cisplatin-treated group
(p,0.05). The CI value of hPK5 or NGR-hPK5 combination with
cisplatin (at a low dose of 0.5 mg/kg/day) was 0.818 and 0.802
respectively, which indicated that they all had a synergistic effect.
To investigate whether the combination therapeutic activity
occurred at the expense of additional toxicity, C57BL/6J mice
were injected i.p. with either PBS or cisplatin, recombinant protein
alone or a combination of both recombinant protein and cisplatin.
As shown in Fig. 8, treatment with hPK5 or NGR-hPK5 was well
tolerated at the dose tested, whereas treatment with cisplatin at a
high dose (2 mg/kg/day) 6 times and 12 times caused 22.62% and
40.60% weight loss respectively compared with the control group.
Cisplatin exhibited antitumor activity in vivo, but weight loss was
also observed. Combination therapy of recombinant protein
(hPK5 or NGR-hPK5) and cisplatin did not result in additional
weight loss compared with cisplatin treatment. These results
suggested that hPK5 or NGR-hPK5 could enhance antitumor
effects of cisplatin without causing significant weight loss.
Discussion
Angiogenesis plays a key role in tumor progression [34]. It was
hypothesized that inhibition of angiogenesis would be an effective
strategy to treat human cancer, and an active search for
angiogenesis inducers and inhibitors began in 1971 [34]. Several
endogenous angiogenesis inhibitors are protein fragments derived
from extracellular matrix [35] or hemostatic system proteins [36].
Plasminogen is a blood protein that is proteolysed into potent
angiogenesis inhibitors, such as angiostatin (kringles 1–4), kringles
1–5, kringles 1–3, and kringle 5 [12]. Among them, K5 displays
the most potent inhibitory activity to endothelial cell proliferation
and migration [15,16] among known naturally occurring angio-
genesis inhibitors. Several reports have shown that hPK5 has a
potential therapeutic effect in angiogenesis-related diseases,
including solid tumors. For instance, Perri et al observed that in
a nude mouse orthotopic brain cancer model tumor-targeted
hPK5 expression was capable of effectively suppressing glioma
growth and promoting significant long-term survival (.120 days)
of test animals [25]. The hPK5 induced a marked reduction in
blood vessel formation and significantly suppressed the recruit-
ment of tumor-infiltrating CD45
+ Mac3
+ Gr1
2 macrophages [25].
Successive studies have suggested that hPK5 could have thera-
peutic potential in hepatocellular carcinoma [20–22], lung cancer
[23,24], glioblastoma [25,26], ovarian cancer [27] etc. In our
previous study, we explored the therapeutic alliance of radiother-
apy and hPK5 to inhibit the LLC tumor growth in tumor-bearing
animals [28]. The results indicated that there was a significant
synergistic effect between radiotherapy and hPK5 antiangiogenesis
treatment, compared with each single treatment method. The
mechanism of synergy might be due to that hPK5 increased the
in other tissues except for kidney in which the level of NGR-hPK5 was lower than that of hPK5 at 6 h. N=3. B, The tumor-to-normal tissue ratios of
NGR-hPK5 and hPK5 at 1 h and 6 h post-injection were calculated from A.*p,0.05 compared with hPK5.
doi:10.1371/journal.pone.0037132.g005
Figure 6. Immunofluorescence analysis of neovascularization in tumors. LLC tumor-bearing C57BL6/J mice were systemically treated with
control saline or with 2.5 mg/kg/day of hPK5 or NGR-hPK5 daily for 5 days, and primary tumors were resected on day 1 after post-treatment. A, The
immunofluorescence analysis was evaluated for visualization of CD31-positive endothelial cells. DAPI counterstain was used to visualize nuclear
detail. B, Microvessel density per field (6200) of experimental group and saline-treated group. The data shown were the mean 6 SD. Microvessels
were counted from three most vascular areas (‘hot spots’) fields in tumors from three mice in each group. Bar=20 mm, * p,0.05 compared with
control, ‘ p,0.05 compared with hPK5.
doi:10.1371/journal.pone.0037132.g006
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radiation. It has been suggested that hPK5 acts as a novel anti-
cancer agent, resulting in a potent, clinically relevant antitumor
effect.
In the current study, coupling hPK5 with NGR peptide
improved its antineoplastic activity and only low doses of NGR-
hPK5 were needed for effective therapy by the vascular targeting
strategy. Because the function of NGR peptide is dependent on its
conformational characteristics, we simulated the three-dimension
structure of hPK5 using Cn3D 4.1 program to determine the
spatial positions of amino and carboxyl terminus. Both amino and
carboxyl terminus were localized at the surface of the molecular
structure (data not shown). Therefore NGR peptide being fused to
NH2- or -COOH terminus of hPK5 could not have a great effect
on its binding activity to CD13.
Giorgio et al [37] investigated the structure and tumor-homing
properties of cyclic CNGRC-TNF a (containing disulfide bridge)
and linear GNGRG-TNF a conjugates, and compared their
antitumor activity. Experiments carried out in animal models
showed that both linear GNGRG and cyclic CNGRC could target
TNF a to tumors. However, the antitumor activity of CNGRC-
TNF a was over 10 times higher than that of GNGRG-TNF a.
The molecular dynamic simulation showed that the NGR motif
had a strong propensity to form b-turn (Gly
3-Arg
4) in linear
peptides, and the disulfide bridge constraint was critical for
stabilizing the bent conformation and for increasing the tumor
targeting efficiency. In the present study, cyclic CNGRC was
selected to modify hPK5 at its amino terminus via a Gly4 linker to
ensure that the function of NGR peptide and hPK5 could not
influence each other.
APN expresses at a high level in tumor vasculature and plays an
important role in angiogenesis [2]. APN is up-regulated in
response to hypoxia and to angiogenic growth factors, such as
basic fibroblast growth factor (bFGF) and vascular endothelial
growth factor (VEGF), and its signals regulate capillary tube
formation during angiogenesis [38]. Moreover, studies have
revealed that APN/CD13 is a marker for semiquiescent cancer
stem cells (CSCs), and its elevated expression correlates with tumor
Figure 7. Tumor growth suppression in C57BL/6J mice bearing LLC tumors treated with hPK5/NGR-hPK5 and cisplatin. When the
tumor size reached about 50 mm
3, the mice were injected i.p. every other day with hPK5/NGR-hPK5 (on days 0, 2, 4, 6, 8 and 10; 6 times totally) and
24 h after each treatment mice were injected i.p. with cisplatin (on days 1, 3, 5, 7, 9 and 11; 6 times totally). The dose of hPK5 or NGR-hPK5 was
1.25 mg/kg/day in all protein therapy groups. Control mice were treated with injections of PBS. A, hPK5 combined with 2 mg/kg/day of cisplatin; B,
NGR-hPK5 combined with 2 mg/kg/day of cisplatin; C, hPK5 combined with 0.5 mg/kg/day of cisplatin; D, NGR-hPK5 combined with 0.5 mg/kg/day
of cisplatin. Tumor volume was calculated by the formula (L6W
260.52). Eight to ten LLC tumor-bearing mice were used in each sample unit, and the
data shown were the mean volume 6 SE. * p,0.05.
doi:10.1371/journal.pone.0037132.g007
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functional inhibitors to APN blocked retinal neovascularization,
chorioallantoic membrane angiogenesis, and tumor growth [2].
The addition of an NGR-sequence at the amino terminus of
endostatin resulted in strong binding and inhibition of endothelial
cell APN [11]. Yokoyama et al reported that NGR-endostatin
showed increased binding to endothelial cells and had higher
tumor localization than the native protein, and increased binding
of endostatin also coincided with improved antiangiogenic
properties of endostatin [11].
Therefore, addition of a peptide that contains NGR could
promote both NGR-dependent and -independent signaling via
APN/CD13, resulting in potent antiangiogenic activity of hPK5.
In this study, hPK5 was genetically modified to introduce an NGR
motif (NGR-hPK5) and was expressed in GS115. The effect of
NGR-hPK5 treatment on early tumor neovascularization was
examined by measurement of microvessel density (Fig. 6). Hlatky
et al [42] caution that although microvessel density is a useful
prognostic marker, it is not, by itself, an indicator of therapeutic
efficacy. Microvessel density alone is insufficient to distinguish
between an angiogenic activity that is directly disrupting pathways
governing vessel growth and an activity that alters the metabolic
burden of the supported tumor cells. Thus additional assays for
evaluating the antiangiogenic efficacy of NGR-hPK5 were
included. The biological activity of NGR-hPK5 was assessed
and compared with that of hPK5 by endothelial cell proliferation,
migration, cord morphogenesis assays and CAM assay (Fig. 2).
NGR-hPK5 exhibited directly increased antiangiogenic activity in
vitro and in vivo. Our data (Fig. 4 and Fig. 5) also showed that
NGR-hPK5 was localized to tumor tissues at a higher level than
wild-type hPK5.
99 mTc-labeled hPK5 and NGR-hPK5 were
determined in tumor and major organs by planar imaging and
biodistribution studies from 0.5 h to 6 h post-injection. The tumor
uptake of NGR-hPK5 was significantly higher than that of hPK5
at each time point (approximately 3-fold). Increased accumulation
of NGR-hPK5 correlated with stronger antiangiogenic effects in
vivo. Only one-fifth the dose of NGR-hPK5 was needed for a
similar antitumor effect produced by wild-type hPK5. These
studies indicated that NGR modification could enhance anti-
angiogenesis activity of hPK5 by targeted delivery to the tumor
vasculature and improved the antitumor activity of hPK5.
Preclinical studies have shown that in vivo frequently protracted
administration of low dosages of conventional chemotherapeutic
drugs on a metronomic or antiangiogenic schedule could also
damage or kill the endothelial cells of tumor neovasculature and
delay acquired resistance to these chemotherapeutic drugs [43–
45]. Tan et al [44] explored the efficacy of a strategy combining
low-dose cisplatin and a recombinant xenogeneic endoglin as an
antiangiogenic protein vaccine. The combination therapy resulted
in not only significant antiangiogenic effects but also additional
promotion of tumor cell apoptosis and inhibition of tumor cell
proliferation, without any ensuing increase in host toxicity during
treatment. In addition, the combination demonstrated a synergis-
tic relationship, which was shown in all of the synergistic indexes,
i.e., tumor volume, angiogenesis, apoptosis and proliferation.
Other findings have also suggested that vascular targeting could
increase vascular permeability, alter tumor barriers and increase
the penetration of chemotherapeutic drugs [46,47]. Cisplatin is
widely used in the treatment of human tumors [48]. However, the
potential for tumor control with cisplatin chemotherapy must
always be carefully balanced with the risk for normal tissue
damage [49,50]. In the current study, though cisplatin at a high
dose could produce a significant antitumor response, significant
systemic toxicity such as weight loss was observed. Cisplatin at a
low dose exerted modest antitumor effect with decreased toxicity,
whereas cisplatin in combination with hPK5 or NGR-hPK5
significantly enhanced the therapeutic effect. At the same dose,
combination therapy with NGR-modified hPK5 and cisplatin
resulted in a stronger inhibition of tumor growth than the
combination therapy with hPK5 and cisplatin. It indicated that
vascular targeting could be a novel strategy for increasing the
therapeutic index of chemotherapeutic drugs.
In our studies, we successfully expressed NGR-hPK5 in yeast
and purified the new protein. In vitro and in vivo NGR-hPK5 had
stronger antiangiogenesis activity than wild-type hPK5, which
indicated that NGR modification of antiangiogenic molecules,
such as hPK5, could be used to improve their therapeutic efficacy.
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Figure 8. The effect on body weight analysis of hPK5/NGR-
hPK5 and cisplatin. C57BL/6J mice were injected i.p. with either PBS
or cisplatin, recombinant protein alone or combined with cisplatin. On
day 1 after post-treatment, the body weight was observed. A, Control
(PBS); B, Cisplatin at 2 mg/kg/day dose every other day (6 times totally);
C, Cisplatin at 2 mg/kg/day dose every day (12 times totally); D, hPK5 at
1.25 mg/kg/day dose every other day (6 times totally); E, hPK5+cisplatin
(B); F, NGR-hPK5 at 1.25 mg/kg/day dose every other day (6 times
totally); G, NGR-hPK5+cisplatin (B). Five mice were used in each sample
group, and the data shown were the mean volume 6 SD. * p,0.05
compared with control.
doi:10.1371/journal.pone.0037132.g008
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